clinical trial · NCT06104449
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
Merck Sharp & Dohme LLC·phase1·active not recruiting·n = 6
Prostatic NeoplasmsMetastatic Castration-Resistant Prostate CancerOpevesostatDexamethasoneFludrocortisone acetateHydrocortisone
brief summary
The purpose of this study is to assess the efficacy and safety of opevesostat in the treatment of Japanese men with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Next Generation Hormonal Agent (NHA) and taxane-based chemotherapy.
started
Nov 14, 2023
primary completion
Feb 20, 2026
completion
Apr 20, 2026
last updated
Mar 6, 2026
detailed description
After approval of Protocol amendment 03, participants in the survival follow-up phase will have a final survival contact and then be discontinued from the study.
official title
A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol